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Abstract 
 
Several studies in the field of tissue engineering have led to the 
conclusion that the success of a graft designed to ensure the 
regeneration / repair of a tissue is closely related to its ability of 
inducing the formation of a vascular network capable of supporting 
the function of those cells that will make up the newly formed 
tissue. 
In tissue engineering in fact, angiogenesis - the development of new 
blood vessels from existing ones - is a process of fundamental 
importance in many physiological processes such as normal tissue 
growth, being responsible of creating a vascular network capable of 
providing oxygen and nutrients to the neo-formed tissue. 
Vessel formation is characterized by several stages such as the 
recruitment and differentiation of endothelial progenitor cells, and 
is mediated by specific soluble growth factors, such as Vascular-
Endothelial Growth Factor. 
Biocompatible scaffolds represent a valuable structural support, but 
also as a potential guide for regenerative processes. They must 
satisfy specific physical and mechanical properties, such as a high, 
interconnected porosity, mechanical strength and in addition to 
satisfying the obvious requests of biocompatibility, it is envisioned 
that next-generation scaffolds will be designed with the capability 
of controlling a specific bio-signals release. 
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This work aims to analyze the bioactive potential of a scaffold 
designed with a “bottom up” technique in which the construct is 
seen as the assembly of single units (building blocks) each with its 
on specific, pre-designed, function. 
Followig the bottom-up paradigm, we developed an assembly 
procedure based on solvent sinterization of microspherical building 
blocks. Constructs fabricated by this technique, are multifunctional 
polymer scaffolds with predefined pore dimension and high 
interconnectivity. These constructs were loaded with interspersing 
PLGA drug delivery systems (DDSs) for the release of angiogenic 
factors or similar molecules. 
Specifically, QK, the "engineered VEGF mimicking peptide" was 
loaded onto these DDS.  
We wanted to demonstrate that QK maintains its pro-angiogenic 
activity in the context of an application in which PCL scaffolds, 
made following a bottom up approach, are loaded with DDS 
controlled release.  
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Chapter 1 
 
1. Introduction 
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1.1. Vascular tissue development 
 
Vascularization is a key factor in tissue engineering (TE) supporting 
the successful integration of grafts inside the host body. The 
vascular system provides a number of critical functions, including 
the delivery of oxygen and nutrients to all parts of the body, 
transport of metabolic waste products, and delivery of circulating 
soluble factors, and stem and progenitor cells [1]. Development of a 
stable and functional vascular system depends on the balance of the 
angiogenic signals and other signals that promote the regression of 
vessel themselves. Indeed, in pathological conditions, the 
angiogenic process is very abnormal due to an alteration of this 
homeostasis. 
Vascularization is initiated during embryonic development, and the 
development of the cardiovascular system precedes the 
developments of all other organs in the embryo due to its central 
importance [2]. Vascularization continues during postnatal growth 
and in the adult during the menstrual cycle, inflammation and 
wound healing. It is generally believed that neovascularization 
includes three processes, namely vasculogenesis, angiogenesis, 
arteriogenesis [3]. In the embryo, vasculogenesis is the de novo 
vessel network formation from angioblasts or endothelial progenitor 
cells that migrate, proliferate and differentiate to form endothelial 
cells, and subsequently organize into cord-like structures as the 
primary plexus [4]. 
Angiogenesis refers to the process of blood vessel sprouting from 
preexisting capillaries, and includes subsequent remodeling 
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processes such as pruning, vessel enlargement, and intussusceptions 
(vessel splitting) to form stable vessel networks [5]. This process 
unfolds in four phases characterized by different genetic programs 
that include the activation and migration of existing mature 
endothelial cells, degradation and remodeling of extra cellular 
matrix (ECM), endothelial cell proliferation and the formation of 
new blood vessels. These phases are summarized hereunder: 
 Recruitment and differentiation of endothelial progenitor 
cells by soluble factors (VEGF, P1GF, Ang1, cytokine) 
  Quiescent of endothelial cells and interaction with the 
major component of the ECM  
 Activation of ECs, proliferation, migration through the 
release of metalloproteinase (MMPs) and plasmin 
 Differentiation and morphogenesis of endothelial cells. 
Recruitment of smooth  muscle cells (SMC) by soluble 
factors 
 Stabilization of vessels 
Under the action of angiogenic factors, endothelial cells produce 
proteolytic enzymes (MMPs) that degrade the basement membrane 
of pre-existing capillary and express specification integrins for 
migration. Endothelial cells migrate towards the source of the 
angiogenic factor where they will form a new vessel. 
Finally, arteriogenesis mainly denotes the enlargement of arterial 
vessels to adjust for lost flow in other vessels [6] and these terms 
are also used at times to include the process of remodeling of 
existing capillaries to form arterioles [7]. 
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All vascularization processes involve a series of interactions among 
cytokines, growth factors, various types of cells and enzymes. 
Numerous growth factors involved in vasculogenesis have been 
identified and characterized, including vascular endothelial growth 
factor (VEGF) Fibroblast growth factor (FGF), Placenta growth 
factor (PIGF), Hepatocyte growth factor (HGF), Platelet-derived 
growth factor (PDGF), Angiopoietin-1 and Angiopoietin-2, insulin-
like growth factor (IGF), granulocyte macrophage colony-
stimulating factor (GM-CSF), and monocyte chemo-attractant 
protein-1 (MCP-1). The mechanism that regulates this interaction is 
altered either by a reduction of inhibitory factors - as it happens in 
most common heart disease - or by excessive production and release 
of pro-angiogenic factors, typical of tumor-associated angiogenesis. 
 
1.2.   3D Scaffold for bone regeneration 
 
In order to regenerate a natural tissue the use of a three-dimensional 
structure inducing tissue re-growth with specific stimuli seems 
mandatory. Recent studies show that isolated cells are hardly 
capable of organizing them spontaneously to form complex tissue in 
absence of three-dimensional structures able to guide and stimulate 
their activity [8]. The three-dimensional tissue regeneration 
requires, therefore, a support (scaffold) that emulates the 
extracellular matrix for the organization of cells in complex 
structures.  A well-designed, three dimensional scaffold is one of 
the fundamental tools to guide tissue formation in vitro and in vivo. 
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The role of the scaffold is to induce tissue regeneration by 
providing a “temporary guide” for cell growth, under appropriate 
culture condition, to facilitate the process of differentiation [9]. In 
this work we have focused mainly in the creation and analysis 
applications with bone grafting. 
 
1.2.1. Properties of the scaffolds 
 
Mechanical stability and specific biological compatibility are 
features of uttermost importance for tissue-engineering constructs. 
Consequently, we must consider two distinct sets of parameters 
during the design phase: biological parameters, related to the cells 
contacting the scaffold, and engineering parameters, related to the 
mechanical and micro structural features of the tissue to mimic. 
This affects the materials choice (natural or synthetic) especially in 
a bone-grafting context, so they will satisfy various requirements: 
 Biocompatibility is necessary to avoid unwanted host tissue 
response to the implant.  Biocompatibility is linked to the 
need of improving and/or restoring a specific biological 
function, without interfering or interacting in a harmful way 
with the physiological activity of the organism [10]. It is 
also understood that an ideal scaffold should promote 
vascular invasion within few weeks of implantation to 
actively support nutrient, oxygen and waste transport [11]. 
Beyond biocompatibility, bioactivity is seen as a plus. 
Scaffolds should mimic the structure and biological function 
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of the extracellular matrix; they should support ECM 
formation by promoting cellular function, and have the 
ability to provide biochemical signals to the cells. In the 
case of bone formation an ideal scaffold should also be able 
to recruit progenitor cells through bio-molecular signaling, a 
property known as osteoinduction. 
 The materials used must show mechanical properties (elastic 
modulus, responses to applied loads) that are compatible 
with those of the replaced tissue. In vivo, the engineered 
structure should retain sufficient mechanical strength to 
tolerate any stress and physiological load imposed on it [12]. 
Mechanical properties of bone vary widely from cancellous 
to cortical bone. In particular, Young’s modulus of cortical 
bone is between 15 and 20 GPa and that of cancellous bone 
is between 0.1 and 2 GPa. Compressive strength varies 
between 100 and 200 MPa for cortical bone, and between 2 
and 20 MPa for cancellous bone. The large variation in 
mechanical property and geometry makes it difficult to 
design an ideal bone scaffold [13]. 
In addition to the basic material requirements, tissue 
engineering has also highlighted the importance of macro and 
micro structural properties of the scaffold. Some morphological 
properties play a crucial role on the survival, growth, diffusion 
and reorganization of cells. The properties of the scaffolds 
essential for cell growth are: 
 High and interconnected porosity. The ideal scaffold must have 
a highly porous structure. Pores interconnection is a prerequisite 
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for a uniform cells distribution in space, their survival, 
proliferation and migration in vitro and it should as well provide 
the necessary space for the neo-vascularization of the 
surrounding tissue in vivo. High porosity and pores 
interconnection allow the use of bioreactors to create 
hydrodynamic microenvironments with a minimum number of 
constraints to the diffusion, which strongly reflect the fluid-
dynamic conditions in vivo to obtain an extensive and well 
organized community of cells [12]. In an ideal scaffold pore size 
should be at least 100 μm in diameter for successful diffusion of 
essential nutrients and oxygen for cell survivability [14]. 
However, in bone tissue in-growth, pore sizes in the range of 
100-150 and 150-200 μm are found to be optimum, while 
smaller pores (75-100 μm) resulted in ingrowth of un-
mineralized osteoid tissue, and even smaller pores (10-75 μm) 
were penetrated only by fibrous tissue [15]. Conversely, a high 
porosity reduces the mechanical properties (e.g. compressive 
strength) and increases the complexity of scaffold 
manufacturing process. 
 Bioresorbability is another crucial factor for scaffold in tissue 
regeneration. An ideal scaffold should be able to degrade with 
time in vivo, preferably at a controlled resorption rate and 
eventually creating space for the new bone tissue to grow. 
Naturally, designing and manufacturing multi-scale porous 
scaffolds having ideal composition including targeted 
biomolecules, mechanical properties and related bioresorbability 
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are some of the key challenges towards their successful 
implementation in tissue engineering. 
 
1.2.2. Biomaterials used for scaffold fabrication 
 
Polymeric materials most widely used in the biomedical field and, 
more specifically, in tissue engineering, can be natural or synthetic.  
The natural materials used [16] often have the advantage of specific 
cellular interactions, the so-called “cell recognition”. These 
materials are either components of or have macromolecular 
properties similar to the natural ECM. However, the main issue 
concerning materials taken from human or animal tissues is their 
scarcity. The most natural materials used in tissue engineering are 
collagen, alginates, chitosan and hyaluronic acid (HA). Collagens 
are the main protein of mammalian tissue ECM and comprise 25% 
of the total protein mass of most mammals [17], [18]. Similarly, HA 
is found in varying amounts in all tissues of adult animals. HA, both 
alginate and chitosan are hydrophilic, linear polysaccharides [19]. 
They interact in a favorable manner in vivo, and thus have been 
utilized as hydrogel scaffold materials for tissue engineering [20]. 
Conversely, these materials have a limited versatility in scaffolds 
construction in terms of mechanical properties. In contrast, 
synthetic biopolymers offer an advantage over natural materials in 
that they can be industrially reproducible on a large scale. They can 
be also tailored to give a wide range of properties (in terms of 
structure and degradation rate) which are more predictable and 
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controllable. In particular, many investigations focused on synthetic 
biodegradable polymers that are already approved by the Food and 
Drug Administration (FDA). The main drawback of synthetic 
polymers is the lack of specific signals for cellular recognition. 
Synthetic polymers widely used in tissue engineering are 
biodegradable polyesters such as Polyglycolic Acid (PGA), 
Polylactic acid (PLA), Polycaprolactone (PCL). PCL consists of 
five non-polar methylene groups and a relatively polar ester group. 
The PCL degradation kinetics is very slow when compared to PLA, 
PGA. Consequently, it is suitable for long term sustained drug 
delivery extending over a period longer than one year [21]. The 
polyesters are relatively rigid materials and this is an advantage in 
load-bearing applications, and it is a disadvantage when mechanical 
continuity with the soft tissue or blood veins is required. Finally, 
none of these polyesters has chemically reactive functional groups 
for easy adhesion of drugs or biologically active media [12]. 
 
1.2.3. Techniques in scaffold fabrication 
 
Several technologies have been developed to process synthetic and 
natural scaffold materials into porous structures. The techniques 
used depend on the polymer employed and the application of 
interest. To outline the state of the art, it first is necessary to 
distinguish between two different production approaches: namely 
“top-down” or “conventional techniques” and “bottom-up” or “non 
conventional techniques” (Table 1). Most commercially available 
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tissue engineering approaches are “top-down”, meaning that 
through a series of chemical or physical reactions it is possible to 
process a bulk material in order to obtain a given structure with 
certain characteristics. Traditional technologies include solvent 
casting, gas foaming, phase separation and many others. 
 
Top- Down Techniques Bottom-up Techniques 
Solvent casting/ Particulate 
leaching 
3D printing 
Gas foaming Stereolitography 
Phase separation Selective laser sintering (SLS) 
electrospinning Fused deposition model 
 Microspheres sintering 
Table.1 Top-down and bottom-up techniques to fabrication scaffold 
 
 However, scaffolds fabricated by these techniques do not 
adequately mimic the structure of the natural extracellular matrix in 
terms of architecture, which may be one of the reasons for 
suboptimal outcome in generating functional tissues In bottom-up 
approaches, scaffolds are fabricated assembling smaller building 
blocks. The unconventional techniques, also known as rapid 
prototyping (RP) or solid free-form fabrication (SFF), provide 
exceptional spatial control over the architecture of the polymer. 
They are based on the use of automated image processing systems 
that enable a computer-assisted design and fabrication, respectively 
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performed by CAD (computer-aided design) and CAM (computer-
aided manufacturing). RP techniques can rapidly produce 3D 
objects using layer-by-layer manufacturing methods. They 
generally comprise the design of a scaffold modeled by using the 
CAD software that is subsequently broken down into a series of 
cross sections. For each cross section, a RP machine lays down a 
layer of material starting from the bottom and moving up a layer at 
time to create the scaffold. RP techniques are the most advanced 
techniques for scaffold fabrication. They can produce the parts with 
highly reproducible architecture and compositional variations. RP 
techniques have advantages over other fabrication techniques such 
as the ability to control matrix architecture (size, shape, 
interconnectivity, branching, geometry and orientation) yielding 
biomimetic structures varying in design and material composition. 
They also grant control over the mechanical properties and 
degradation kinetics of scaffold. One of the main drawbacks of 
these techniques is the trade-off between resolution and 
manufacturing speed achieved by current systems and a not so wide 
range of polymeric materials that can be used. 
 
1.3.   Importance of Growth Factors release in regenerative 
medicine 
 
In order to overcome the difficulties of using artificial implants and 
organs transplantation, scientific research has focused his interest 
on regenerative medicine, leading to the formation of a new science 
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intersecting medical-biological skills and other disciplines related to 
engineering. The purpose of this multidisciplinary field is to restore 
the loss of physiological functions by replacing the organs and 
tissues diseased or damaged [8]. In the bone-grafting context, these 
pathological degenerations have been traditionally repaired utilizing 
autografts and allografts, because of their osteoconductivity, 
osteoinductivity and osteogenecity. Nonetheless their application is 
restricted because of donor shortage and donor-site morbidity [22] 
[23] as well as inconveniences associated with their transplantation 
such as immune rejection and pathogen transfer [24]. The branch of 
regenerative medicine known as Tissue Engineering (TE) was 
developed to overcome these limitations [25]. The National Science 
Foundation officially coined this term in 1988, indicating that the 
aim of this multidisciplinary field was to produce biological 
substitutes containing – or recruiting – living and functional cells 
for regeneration, maintaining or improving performance of the 
tissue [26]. Therefore TE integrates different disciplines such as 
medicine, biology, engineering and chemistry with the common aim 
of obtaining or replacing organs or parts of organs in the human 
body employing three fundamental “tools”; namely cells, scaffolds 
and growth factors (GFs) which, however, are not always 
simultaneously used [27]. On the other hand, recent experimental 
and clinical studies indicate that the success of any TE approach 
relies on the delicate and dynamic interplay among these three 
components and that functional tissue integration and regeneration 
depend upon their wise coordination [28]. Future generation 
scaffolds will have to provide not only the adequate mechanical and 
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structural support but also actively guide and control cell 
attachment, migration, proliferation and differentiation. This is in 
theory achievable if the scaffold function is extended to supply 
biological signals guiding and directing cell function thought a 
combination of matricellular cue exposition and GF sequestration 
and delivery [28]. A series of undesirable systemic effects such as 
toxicity, an insufficient local concentration and their rapid 
degradation is releated to the administration of the bolus of GF. 
Indeed, when a solution of the growth factor is injected into the site 
requiring regeneration, the biological effect cannot be always 
predicted. This is because the growth factor is rapidly diffused away 
from the injector site. To overcome the problem of in vivo 
instability, GFs are administered in polymeric vehicles to locally 
deliver the factor in a controlled, localized way for the desired time 
frame. Growth factors can be incorporated into the polymeric 
delivery systems in different ways, so the drug delivery systems 
(DDS) is able to enhance their activity [29]. It is possible that, when 
used in combination with an appropriate DDS technology, the 
growth factor enhances the in vivo proliferation and differentiation 
of key cells that promote tissue regeneration. It is possible to protect 
the growth factor against proteolysis, as it is incorporated in the 
release carrier for prolonged retention of the activity in vivo. DDS 
technology can be also useful for half-life prolongation, adsorption 
improvement and targeting, applicable in tissue engineering using 
protein and genes. 
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1.3.1. Type and mechanism of action 
 
Growth factors are soluble macromolecules that define the 
biological environment. GFs are protein molecules specific for 
intercellular and cell-ECM signaling, which are involved in ECM 
dynamic properties through specific surface receptors, driving GFs 
regulatory activity [30]. Growth factor signaling starts up the 
specific cellular response of a very wide range of cell actions, 
including cell survival, and control over migration, differentiation 
or proliferation of a specific subset of cells. Initially the growth 
factor, which is secreted by the producer cell, goes to bind specific 
trans-membrane receptors on the target cells so to instruct cell 
behavior (Fig. 1). The machinery that traduces the growth factor-
binding signal to the cell nucleus involves a complex array of 
events involving cytoskeleton protein phosphorylation, ion fluxes, 
changes in metabolism, gene expression, and protein synthesis and 
ultimately an integrated biological response [31]. Growth factors do 
not act in an endocrine fashion but differ from other 
oligo/polypeptide molecules, such as insulin and hormones, in the 
mode of delivery and response elicited. In fact, they exhibit short 
range diffusion through the extracellular matrix and act locally 
because of their short half-lives and slow diffusion. There are 
different ways to deliver particular signals of the growth factors that 
depend on not only their ability to diffuse though the extracellular 
matrix (ECM), but also depending on the target cell density, type of 
receptors that follow in an intracellular signals transduction. In this 
way, the same receptor can translate different messages depending 
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on the intracellular transduction pathways, which can differ from 
one cell type to another. The ultimate response of a target cell to a 
particular soluble growth factor can also be governed by external 
factors, including the ability of the factors to bind to ECM, ECM 
degradation and growth factors concentration and cell target 
location [29], [32]. 
 
 
Figure.1 Cross talks between cells mediated by growth factors and ECM. The 
producer cell secretes soluble growth factors that bind to target cell receptors. 
[33] 
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1.3.2. Strategy for presentation of GF  
 
There are several strategies we can pursue to control the release of 
growth factors from the scaffold, but some points should be 
considered first: 
 The load capacity corresponds to the amount of growth 
factor that can be mixed into the scaffold; 
 The distribution relates to the way the growth factor is 
dispersed, which will influence the release kinetics; 
 The binding affinity defines how tightly a growth factor 
binds the system; this must be sufficiently low to allow 
release, but high enough to prevent uncontrolled release; 
 The release kinetics: its control allows the appropriate dose 
of growth factor to reach the cells over a given period of 
time; 
 The long-term stability: the system should enable growth 
factor to maintain their structure and activity over a 
prolonged period of time; 
 The economical viability: such biomaterials must further be 
easy to manufacture and to handle, and be cost-competitive: 
The strategies used in TE for growth factor presentation of 
biomaterial constructs are mainly two: 
 Chemical immobilization of the growth factor into or onto 
the matrix; 
 Physical encapsulation of growth factors in the delivery 
system [29]. 
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Chemical methods have been investigated, but often result in the 
denaturation and activity lowering of protein because the functional 
groups of protein are chemically modified by immobilization 
reaction. Therefore, physical methods are preferable for growth 
factor integrity. In fact, such a physical immobilization is often 
observed in growth factors existing in the body [30]. Some growth 
factors are naturally stored in the body; they are stored ionically 
with the acidic polysaccharides of ECM (such as heparin sulfate and 
heparin) because most of them have a positively charged site on the 
molecular surface. It is widely accepted that, when needed, the 
complexed growth factor is water solubilized by the enzymes 
secreted from the surrounding cells released from the ECM 
complex during ECM degradation. This complexation also protects 
growth factors from their denaturation and general enzymatic 
degradation in vivo. 
 
1.4.   Time controlled in delivery system 
 
In the field of pharmaceutical technology there are formulations that 
can release drugs in the body in amount and at controlled rates. It is 
possible to program the delay, the speed and the release of active 
molecules by numerous pharmaceutical forms. Those formulations 
are defined controlled drug delivery systems (DDS) that minimize 
unwanted side effects such as under or over dosing of drug. The use 
of this DDS can provide several advantages over traditional 
methods of administration, among them, DDS provide protection of 
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drugs, especially protein, that are otherwise rapidly destroyed by the 
body. Finally, DDS can increase patient comfort and compliance by 
replacing frequent (e.g., daily) doses with infrequent (once per 
month or less) injection. However, there are potential disadvantages 
that should not be overlooked. Possible toxicity of the materials 
used, dose dumping, requirement of surgical procedures to implant 
or remove the system, and higher manufacturing costs are 
disadvantages of using drug delivery system. DDS main advantage 
and disadvantage are summarized in Table 2. A large number of 
classes of drugs that include chemotherapeutic drugs, [34] 
immunosuppressant’s, [35] anti-inflammatory agents, [36]-[37] 
antibiotics,  [38]-[39] opioid antagonists, [40] steroids, [41]-[42] 
hormones,  [43] can benefit from temporal or distribution controlled 
release.  
 
Table.2 DDs advantage and disadvantage 
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DDS can be produced by using natural or synthetic polymers, which 
can be biodegradable or non-biodegradable. (Table 3) These 
polymeric systems can be used in the release of drugs, protein and 
cells and they should present a set of properties that make them 
suitable materials to interact with the human body. One of the most 
important feature is biodegradability of the polymers, their 
degradation products should be normal metabolites of the body or 
products that can be metabolized and easily cleared from the body 
[44]-[45]. Moreover, synthetic polymers are used to develop new 
DDS with specific properties (chemical, interfacial, mechanical and 
biological) for a given application, simply by changing the building 
block or the preparation technique [46]. 
 
Table 3 Example of protein-peptide controlled release systems based on PLGA 
 
Drug Trade
name
Company Polymer Roule Application
Buserelin 
acetate
Profact®de
pot
suprefact® 
depot
Marion 
Roussel
PLGA s/c implant Prostate cancer
Goserelin 
acetate
Zoladex 
®depot
AstraZeneca PLGA s/c implant Prostate cancer,
endometrioses
Lueprorelin 
acetate
Lupren®de
pot
Enantone® 
depot
trenantone
®
Takedia-Abbot PLGA 3-mounth 
depot 
suspension
Prostate cancer,
endometrioses
Octreotide 
acetate
Sandostatin 
LAR®depo
t
Novartis Pharma PLGA s/ 
suspension
GH suspension,
anti cancer
triptorelin Decapeptyl
®depot
Debiopharma PLGA Monthly
s/c 
injection
LHRH agonist, 
prostate cancer
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1.5. PLGA- based drug delivery system 
 
Poly(D,L-lactic-co-glycolide), PLGA (Figure.2) has shown 
immense advantages, among all the biodegradable polymers, as a 
drug delivery carrier and as scaffold material for tissue engineering 
[47]. These advantages include extended release rates (up to days, 
weeks or months) in addition to its 
biocompatibility/biodegradability and ease of administration. The 
American Food and Drug Administration (FDA) have also 
approved a very large number of drug delivery products based on 
this material [48]. PLGA or PLGA based nano/microcarriers can be 
successfully made to incorporate macromolecular drugs such as 
proteins, peptides, genes, vaccines, antigens, human growth factors, 
etc 
 
 Figure.2 PLGA Structure. 
Several benefits come from the possibility to control drug release 
adjusting various polymer parameters such as molecular weight, 
monomer ratio, drug loading, excipient loading, glass transition 
temperature, to name a few. This led to various medical and 
pharmaceutical applications. The advantage of using particle 
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systems include, in fact, the possibility of administering the 
medication directly to the site of action where the system forms a 
deposit from which the active molecules  can be released and act for 
a prolonged period of time. Based on size, two different categories 
of carriers can be distinguished: microparticles and nanoparticles. 
The most accepted classification reports that particles up to 100 nm 
are considered nanoparticles while the ones from 1 μm up to 1,000 
μm classified as microparticles. Their synthesis can be achieved 
from different techniques [49]. Emulsion polymerization, solvent 
evaporation, ionic gelation, self-assembly nanoprecipitation and 
supercritical fluid technology are some of them [50]. The 
mechanism of release by biodegradable polymeric microspheres 
consists of two stages: the diffusion of the drugs thought the 
polymer matrix and the biodegradation of the polymer matrix itself. 
An autocatalic bulk degradation process governs the release 
mechanism of active molecules from PLGA microspheres. This 
mechanism is affected by many physical and chemical factors, such 
as the initial pH, ionic strength and temperature of the external 
environment, the ratio of the copolymers, the molecular weight, the 
crystallinity and the size of species. In the diffusive-erosive 
mechanism an important role is played by the environment in which 
the drug is released. The particle, in contact with the aqueous 
environment hydrates, water getting inside solubilizes the drug that 
begins to spread through the macroporous structure of the PLGA 
microspheres. The presence of pores and their characteristics 
depend on the preparation techniques (e.g. multiple emulsion 
technique). The release of macromolecules can be prevented by the 
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microporosity of the system. Following the degradation of the 
polymer, micropores increase in size until the transport of the 
macromolecule can take place [51].  
 
1.6. Protein and peptide in PLGA particles: instability and 
inactivation problems 
 
The integrity of protein structures is essential for their function in 
physiological or pathological conditions, but both in vitro and in 
vivo many proteins, peptides are fragile molecules that undergo 
different pathways of instability, and they have limited half-life. For 
this reason they need to be carefully handled.  Unexpected 
unfolding or degradation of a protein may lead to inactive, 
sometimes even toxic products. Protein instability, generally, can be 
divided into two chemical and physical processes. Chemical 
processes include hydrolysis (proteolysis), deamination, 
racemization, oxidation, disulfide formation and β-elimination, and 
involves the formation and destruction of covalent bonds, which 
usually occurs in the primary structure and disulfide bonds. Physical 
stability refers to proteins’ ability to retain their secondary, tertiary 
and quaternary structure, which can be lost by reversible or 
irreversible denaturation through a loss of tertiary structure, 
aggregation and adsorption. A major issue, with PLGA delivery 
systems, is protein stability during preparation, storage and release. 
There are several factors associated with this polymer that may 
cause the destabilization of proteins [52]-[53]. During microspheres 
29 
 
preparation, protein are exposed to conditions that are known to 
cause denaturing and aggregation, namely high shear, elevated 
temperature, exposure to the air/liquid interface, organic solvents 
and the oil in water (O/W) interface. Higher energy emulsion 
methods such as by sonication, homogenization and vortex are 
detrimental to proteins [54]. The addition of an aqueous protein 
solution to an organic solvent can lead to protein denaturation. 
During release from polymer microparticles, proteins are exposed to 
many stresses that can compromise the physical and chemical 
stability of proteins. These include protein rehydration, exposure to 
soluble oligomers, low pH, interaction between protein and 
polymer, loss of stabilizing excipients, and physiological 
temperature. Interaction between protein and polymer, such as 
adsorption can also affect the stability of proteins. Adsorption 
occurs by a hydrophobic interaction between the polymer and the 
hydrophobic interior of proteins and can often lead to the formation 
of insoluble aggregates or irreversible conformational changes [55]. 
Even when adsorption is reversible, it may accelerate other 
deleterious reactions by exposing previously buried residues or 
increasing side chain mobility [56]. 
 
1.7. Stabilization strategies of growth factors in PLGA- based 
delivery systems 
 
Several stabilizers have been shown to effectively improve protein 
stability in the polymer formulation DDS. However individual 
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proteins need to be carefully studied for better selection of 
stabilization strategies. Nonetheless, we can intervene on two 
fronts: during the preparation phase and /or during the release 
phase. 
During preparation, the addiction of excipients, such as BSA [57] 
PEG 400 [58] and others, to the inner aqueous phase that compete 
with the water/organic solvent interface can prevent emulsification-
induced denaturation and aggregation. This approach may be 
particularly useful when PLGA microparticles are loaded with low 
amounts of therapeutically potent proteins. On the other hand, 
increasing the protein concentration during emulsification was 
shown to result in higher absolute amounts of aggregated protein at 
the interface, indicating that multi-layer interfacial adsorption can 
occur [59]. Common surfactants have not been very successful as 
stabilizer in the emulsification step because they seem to have an 
insufficient competition with proteins for the water/organic solvent 
interface, or promotion of organic solvent/protein contacts through 
hydrophobic contacts with both components. Another approach to 
protect proteins against degradation during emulsification has been 
the pre-entrapment in a hydrophilic core, and is subsequently 
encapsulated in PLGA microparticles [60]. During the release phase 
specific stabilization approaches to minimize protein degradation 
associated with the direct environment of (degrading) PLGA are 
often needed. To inhibit the acid-induced degradation of proteins 
within the microparticles during the release (if they occur at all in 
vivo), co-incorporation of water poorly soluble salts of inorganic 
bases, such as magnesium hydroxide, calcium carbonate and 
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bicarbonate sodium is performed [61].  Finally, the addition of 
poloxamamers, such as Pluronics F68, induces a decrease in the 
interactions of the macromolecule with the free carboxyl residues of 
PLGA. [62]  
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Chapter 2 
 
2. Material and methods 
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2.1. Induction of angiogenesis in 3D scaffolds for bone 
regeneration  
 
2.1.1. Vascularization in early bone regeneration 
 
Bone formation and development occur through two distinct 
processes: intramembraneous and endochondral ossification [63] in 
which vascularization plays a key role. In intramembranous bone 
formation, in fact, the matrix is deposited by mature osteoblasts, 
which differentiate from mesenchymal stem cells (MSCs) 
transported through capillaries. Osteoblasts play an important role 
in the balance of resorption and the deposition of bone matrix by 
secreting osteoprotegerin that is an inhibitor molecule of osteoclast 
activity [64]. On the other hand, during the endochondral 
ossification, the chondrocytes secret angiogenic growth factors 
promoting the invasion of blood vessels, which then bring along a 
number of highly specialized cells and replace the cartilage mold 
with bone and bone marrow [65]. Successively blood vessels 
transport osteoprogenitor cells for the deposition of new bones and 
endhotelial cells of blood vessels produce growth factors that 
control the recruitment, proliferation, differentiation and function of 
various cells including osteoblasts and osteoclast [66] [67]. The 
vasculature, thus, plays an important role both as a reservoir of 
bioactive signals necessary for bone morphogenesis [68] and as a 
conduit for the recruitment of essential cells involved in bone 
remodeling. During bone development the balance between 
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cartilage formation and vascular invasion is of fundamental 
importance as any change in this balance leads to growth plate 
thickening and a reduction in bone formation. 
 
2.1.2. The role of VEGF in bone regeneration: neo-
vascularization 
 
During the processes of development, remodeling and repair of 
bone tissue, VEGF plays a crucial role in the phase of 
vascularization. This growth factor is produced by endothelial cells, 
macrophages, fibroblast, smooth muscle cells, osteoblasts and 
hypertrophic chondrocytes and during bone regeneration it is active 
both directly and indirectly on osteoblats differentiation. Directly, 
VEGF promotes migration, proliferation and differentiation of 
osteoblasts, and plays also a mediating role for different 
osteoinductive factors, such as TGF, IGF-I and FGF-2, which up-
regulate VEGF expression in osteoblasts [69, 70]. VEGF acts also 
indirectly on osteoblats by stimulating endothelial cells, and 
producing anabolic factors that improve the bone formation [71]. In 
neo-vascularization, VEGF drives the processes of angiongenesis 
and arteriogenesis by its mitigenic and chemotactic effects and 
facilitates the recruitment of circulating endothelial progenitor cells. 
During angiogenesis EC migration and proliferation start under the 
effect of VEGF that causes immature tube-like structures to branch 
from mature blood vessels and if this signal is removed, these 
nascent vessels regress. Because VEGF has a half-life of 90 min 
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once introduced into a host environment, it is important to provide 
an adequate exposure to VEGF to induce a cellular response [72]. 
VEGF is a 46-kDa glycoprotein that comprises six related proteins: 
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and the placenta 
growth factor. The most studied member of the VEGF family is 
VEGF-A. This family exists in different isoforms derived from the 
same gene by alternative splicing of messenger RNA and defined 
on the basis of the length of the amino acids chain, such as 
VEGF121, VEGF165, VEGF189, and VEGF209 in humans [73]. 
VEGF-A is considered the prototype member in the family, it is the 
predominant factor in the regulation of angiogenesis and endothelial 
cell growth. Similar to most peptide growth factors, VEGF binds to 
the extracellular domain of two tyrosine kinase receptors on the cell 
surface of its target : VEGFR-1 or fsm-like tyrosine kinase 1 (Flt-1) 
and VEGFR-2 or fetal liver kinase 1 (Flk-1) also known as kinase-
insert domain-containing receptor (KDR). VEGF bind induces 
receptor dimerization and autophosphorylation of the intracellular 
kinase domain. The phosporylated tyrosines are docking sites for 
the assembly of multiprotein complexs that start different 
intracellular cascade, ending up in endothelial cell activation. 
Whereas the role of VEGF-1 is still under debate, it is well known 
that VEGFR-2 phosporilation stimulates ECS proliferation, 
migration and survival. It is the predominant factor in the regulation 
of angiogenesis and endothelial cell growth.[74] 
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2.1.3. The role of VEGF- mimetic peptide QK in 
vascularization 
 
Because of the important role VEGF plays in angiogenesis, it is 
considered an important target in the pharmacological. The x-ray 
structure of the complex VEGF/flt-1 d2 shows that the binding 
interface is mainly localized in three regions. One of them is the α-
helix crossing the amino acid sequence 17-25. This region contains 
some of the key residues involved in receptors recognition, so a 
well designed helical peptide represents a tractable target for 
peptide engineering [75]. QK is a linear peptide of 15 amino acids, 
(Acetyl-KLTWQELYQLKYKGI-Ammide) which should interact 
with the VEGF receptors - an important prerequisite for its 
biological activity. The presence of amino acids with intrinsic helix 
preference gives QK its helical fold and on opposite faces of the 
peptide there is an amphipathic feature of the helix, which allows a 
number of medium range ionic, polar and hydrophobic interactions. 
Moreover, QK peptide, which is composed by only 15 amino acids, 
could represent a model for further studies [76] (see Fig. 3). In fact, 
this peptide induces attachment and proliferation of endothelial cells 
and promotes their activation and capillary like formation in vitro 
[77] [76]. In vivo, QK peptide has also shown some therapeutic 
promise, it has mostly been used as a locally delivered soluble 
factor [78]. To improve its activity, QK peptide has been 
immobilized on inorganic substrates [77] and self assembling 
peptide scaffolds [79], but also conjugated to bioactive hydrogels 
[80] and to hydroxypatite through a binding peptide [80]. 
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Figure.3 NMR structure of QK. (a) Superposition of the backbone of the best 20 
CYANA QK structures. (b) Backbone superposition of the QK representative 
structure (yellow) and VEGF helix (red) bound to Flt-1D2. Side chain of the 
interacting residues and the Flt-1D2 electrostatic surface are shown [76] 
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2.2. Scaffold for bone regeneration 
 
2.2.1. Bottom-up approach for tridimensional scaffold 
realization 
 
During the design of scaffolds it is important to gain accurate 
control over their macroscopic properties (i.e., geometry, 
mechanical strength, density, porosity), microstructural ones (e.g., 
size, interconnection of the pores) and on their bioactivation 
(surface functionalization, release of growth factors). For this 
purpose there are several techniques that depend on the type of 
polymer used and the application intended. In recent years, many 
studies focused on the development of porous scaffolds by sintering 
of polymeric microparticles in order to overcome several limitations 
found in conventional techniques, mainly related to the mechanical 
properties, pore interconnection, as well as the use of toxic solvents. 
For this reason, in this work we propose a bottom up approach 
based on the assembly of building blocks by solvent induced 
microparticles sintering to realize multifunctional polymer scaffolds 
with predefined pore dimensions. This approach gives an extra 
degree of freedom since it is possible to include - inside the 
construct - an array of microdepots for the release of bioactive 
molecules. Scaffolds manufactured this way show controlled 
microstructure, chemical stability and a mechanical response 
necessary to support neo-tissue growth. The possibility of 
presenting bioactive agents in a predefined chrono-programmed 
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manner is a feature that can give the promising capability of guiding 
cells and tissue processes. 
Polymeric microsphere sintering is achieved by partial dissolution 
of the microspheres surface to form porous three-dimensional 
structures. Two boundary cases limit the process and can be clearly 
underlined: an initial state in which particles come in contact and a 
final situation in which the pores are utterly closed in a continuous 
matrix. We can obtain a porous material only stopping the process 
between the first and the second stage. This can be done only with 
an accurate control of the process parameters. The use of specific 
solvent/non solvent mixtures under mild temperatures was exploited 
to overcome some limitations intrinsic to thermo labile bioactive 
molecules, such as growth factors, which tend to denaturate with 
temperature. The Flory-Huggins solution theory models the 
interplay between monomer-monomer and monomer-solvent 
interaction in a polymer:solvent mixture.  
 
Figure.4 Representation of a junction point formed between two beads in contact 
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With a specific solvent/non-solvent mixture it is possible to balance 
between polymer dissolution and precipitation. During the 
dissolution step a microsphere can develop bonds with adjacent 
microspheres [81]. (Figure.4)  
 
2.2.2. Scaffold obtained by microspheres sintering 
 
For their regeneration, different tissues require different 
microenvironments, but usually an optimum porosity is a common 
prerequisite. Regarding the regeneration of bone tissue, it is 
important for scaffolds to have an appropriate pore size in a range 
from 200 to 400 μm [82]. Based on literature data, the present work 
focused on the realization of three dimensional structures with pores 
size around 200 um. In order to build a scaffold with such 
characteristic, we used a simple geometric model to calculate the 
right diameter range of the microspheres used (see Fig.5). In this 
model, four rigid spheres of equal diameter are arranged 
symmetrically along the diagonals of the square in which they are 
inscribed. 
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Figure.5-Spheres model schematization 
The characteristic dimension of the cavity between the four spheres 
can be approximated by the diameter of the rigid sphere inscribed in 
it: 
    
 
   
Where: D is the diagonal of the square in which spheres are 
inscribed,   is the initial diameter of the rigid spheres. By simple 
geometric considerations, and based on the available sieves 
dimensions (see Section 2.4) microspheres in the 455-500 μm 
diameter range were used to obtain a pore size of around 200 μm. 
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2.3. Materials 
 
The acid poly (D, L-lactic-co-glycolic acid) (PLGA) 50:50 
(Resomer® RG 504H, i.v. 0:32 to 0:44 dl/g) was purchased from 
Evonik® (Germany). The poloxamer188 (Pluronic ® F68, Mw 
8400, HLB 29), the Poly(ε-captolactone) (PCL)(Mw=65kDa), the 
polyvinyl alcohol (Mowiol 40-88)(Mw=13-23 kDa) and phosphate 
buffer (0.01M Na2HPO4, 0.0027 M KCl and 0.137 M NaCl, pH 7.4) 
were purchased from Sigma Aldrich (USA). Dicklorometane and 
chloroform were purchased from Romil Pure Chemistry 
(Cambridge, GB). PDMS SYLGARD 184 (PolyDimethylSiloxane) 
was purchased from Dow Corning (Germany). All solvents used are 
of analytical grade and HPLC grade and were supplied by Sigma 
Aldrich (USA). The water used was filtered through 0.22 μM filter 
(Millipore, USA). Protected N-Fmoc-amino acid derivatives, acetic 
anhydride, coupling reagents and Rink amide MBHA resin have 
been purchased from Novabiochem. DIPEA is provided from 
Applied Biosystem. All other reagents are commercially available 
from Sigma-Aldric and all solvents are commercially available from 
LabScan. 
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2.4. Scaffold assembly  
 
2.4.1. Polycaprolactone Microparticles 
 
The PCL microparticles were prepared by the technique of oil in 
water (O⁄W) single emulsion with solvent evaporation. Briefly, a 
polymer solution, obtained by dissolving the polycaprolactone in 
dichloromethane(50 ml, 10% w⁄v), is added dropwise into 100ml of 
a aqueous PVA solution (Mowiol ® 40-88 ) with 0.1% of Tween 
21. The presence of such emulsifying agents in the aqueous phase is 
essential for reducing the phenomena of coalescence and 
aggregation of the microspheres during the evaporation of the 
solvent. The two solutions are mixed for three hours at a speed of 
400 rpm, using an electronic stirrer (RZR 2102, 
Heidolph,Germany), so as to allow the complete evaporation of 
volatile organic solvent and in order to obtain the dispersed 
microparticles. After, these microparticles are filtered and washed 
three times with distilled water to remove the emulsifying agents, 
and finally allowed to dry under a chemical hood. 
 
2.4.2. Monolayers  
 
PCL microspheres sieved in the selected size range (455–500 μm) 
were processed into a PDMS alignment mold made up of an array 
of PDMS pillars.  
50 
 
 
Figure.6 PCL microspheres micro-posizioned in PDMS mold 
Each individual microsphere has its own accommodation in this kind 
of structure and four other adjacent microspheres border it. These 
alignment structures allow the arrangement of PCL microspheres in 
layers – or arrays - of 10x10 elements (Fig.6). Successively, a solvent 
(100% anisole) was poured over the microspheres (just a drop of 50 
μL). The solvent sintering solution was immediately rinsed with 
ethanol - a PCL non-solvent - and allowed to evaporate from the 
sintered microspheres. 
 
2.4.3. 3D ordered scaffold  
 
After the creation of monolayers of PCL microspheres, obtained by 
solvent sintering, another alignment structure shaped as a box was 
used to put them in an ordered stack and sinter them together. The 
result is a scaffold in which microspheres are arranged in a 3-
dimensional simple cubic lattice. The alignment mold prevents 
slippage between adjacent layers and provides a complete 
correspondence between the microspheres of adjacent layers. The 
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samples were processed with three different solvent/non-solvent 
concentrations, in order to evaluate their mechanical properties during 
the compression test. The concentrations used are shown in the 
following Table.4. In each case, the solvent/non solvent sintering 
solution was immediately rinsed with ethanol as non solvent and 
allowed to evaporate from the sintered microspheres. All 
microspheres appear sintered together with fully formed 
interconnecting necks. 
Anisole-Ethanol 
30%-70% 
50%-50% 
70%-30% 
Table.4 Three different solvent concentrations anisole/ethanol for the last step of 
ordered 3D scaffold sintering 
 
2.4.4. Qualitative and quantitative analysis: X-ray 
microtomography (micro-CT) 
 
A qualitative and quantitative evaluation of the scaffolds obtained 
was carried out by 3D image analysis using a computerized 
microtomograph, SkyScan1172 (Bruker). Microtomography 
(commonly known as Industrial CT Scanning), like tomography, 
uses X-rays to obtain projection images of a 3D-object that later can 
be processed to obtain a virtual tomografic model made up of several 
cross-sectional images of the object under test. MicroCT technique 
was performed in order to evaluate scaffolds morphology: the 
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optimized processing conditions lead to sintered microspheres 
scaffolds with a well defined three-dimensional microstructure. It was 
also performed in order to quantify the pore size, pore volume and 
overall percentage of interconnected porosity of the sintered matrices. 
Each voxel of a micrograph represents the absorption degree of X-
radiation in an elementary volume. To assess scaffolds porosity in the 
reconstructed images, it is necessary to discriminate between air and 
the absorbing material, a step known as binarization. Binarization is 
carried out by imposing a threshold on the absorption spectrum of 
these images. The result of this operation is a binary image (0/1 
W/B) in which the black and white voxels represent respectively the 
empty volume and the one occupied by PCL. It is up to the software 
then, to count white and black voxels, obtaining the object-to-void 
volume ratio and hence porosity. 
 
2.5. Surface treatment 
 
Surface hydrophobicity has a great influence on cell response in 
vivo and in vitro. As many works show [83, 84] the more 
hydrophilic is the surface of a material, the better cell adhesion on 
that surface will be. Moreover, cell adhesion, spreading and 
proliferation is improved when some serum proteins (like 
fibronectin and vibronectin in culture medium and/or from secretion 
[85, 86]) are preferentially adsorbed on the material surface. PCL, 
which was extensively used in this work, is a semi crystalline linear 
polyester, and surely possesses suitable features for tissue 
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engineering application, such as biodegradably, biocompatibility, 
mechanical strength and flexibility [87]. Nevertheless, its low 
surface wettability, due to its rather high hydrophobicity, adversely 
affects cell attachment and proliferation. In fact, when the cellular 
suspension is placed on top of a porous PCL scaffold the culture 
medium is not adsorbed, resulting in a low initial cell seeding 
density, heterogeneous cell distribution and slow cell growth [88]. 
Several surface treatments are available in order to increase the 
surface hydrophilicity of polyesters, and thus improve cell-material 
interfacing, cell adhesion and enhance cell proliferation and 
functions [89]. Among them, there are temporary treatments such as 
pre-wetting in which the hydrophobic porous polymer scaffold is 
easily pre-wetted in ethanol, which is then exchanged with the 
culture medium. During this treatment there is no change on the 
inherent hydrophobic character of polymer. Another temporal 
method is plasma treatment that can provide a reactive chemical 
environment even on inert surfaces, and change the surface 
properties creating desired functionalities for further polymer 
grafting onto the surface [90]. Finally, Surface NaOH hydrolysis 
can be considered. This technique uses strong alkali conditions (1M 
NaOH acqueos solution) to improve the hydrophilicity of polymeric 
scaffold by the hydrolysis of the ester group (-COOH) of polymer 
to carboxylic acid and hydroxyl group. 
We have modified the surface of the scaffold by two different 
treatments: 
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a) hydrolysis of the surface witch Ethanol\0.1N NaOH mix 
solution (15min, 200 RPM) to increase the percentages of hydroxyl 
(–OH) and carboxylic acid (–COOH) groups on the surface area. 
b) O2 plasma treatment. The plasma treatment was carried 
out on a Gmbh Plasma Deposition System (Model Femto Diener, 
13.53 Mhz, DE) under O2 at 20%. The chamber was evacuated to 
less than 10 Pa before filling with oxygen. After the pressure of the 
chamber had stabilized to a proper value, glow discharge plasma 
was created by controlling the electrical power at a radio frequency 
of 13.56 MHz for a predetermined time (1min). 
 
2.5.1. Water contact angle test 
 
To study the effect of different treatments on the surface of 
bioactive scaffolds, static contact angle measurements were 
performed. The contact angle is the angle, conventionally formed 
by the meeting of a liquid-vapor interface with solid liquid interface 
and it quantifies the wettability of a solid surface by a liquid. The 
surface wetting characteristics were examined with a drop-shape 
analysis system. Deionized water droplets (~ 2 μL) were delivered 
to the sample surface by a syringe at room temperature and the 
droplet configuration was captured with a camera. From the 
measured angle between the droplet baseline and the tangent at the 
water/air boundary, a contact angle was calculated as the average of 
the measured left and right contact angles. For statistical analysis 3 
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contact angle measurements were obtained from three different 
surface regions of three identical samples. 
 
2.5.2. Mechanical characterization 
 
In vitro release studies of QK from sintered scaffolds were made by 
suspending one scaffold in 100 μL of PBS pH 7.4 previously 
filtered through filter pores of 0.22 μm in diameter (Millex®, 
Millipore, USA). The samples were incubated in an incubator at 37 
° C and 50 rpm, to mimic the in vivo conditions. At regular 
intervals of time, the release media removed and replaced with the 
same volume of fresh PBS pH 7.4. The samples taken were 
analyzed by (Q-TOF) LC-MS, to determine the amount of peptide 
released. The results were expressed as μg of QK released per 
scaffold ± standard deviation (SD) of the measurement carried out 
on five different batches. 
 
2.5.3. Cells adhesion test on scaffold surface treated 
 
Specific tests were carried out to evaluate the influence of the two 
surface treatments on the process of cell adhesion. Scaffolds 
(untreated, plasma and EtOH/NaOH treated) were placed in a 96 
multiwell plate and seeded with human umbilical endothelial vein 
cells (HUVECs) suspended in medium in order to obtain a surface 
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concentration of 9*10
3
 cells/cm
2
. The different scaffolds were then 
placed in an incubator at 37° C with a controlled atmosphere at 5% 
CO2. After 72 h of incubation cells adhered to different scaffolds 
were counted through the Burker chamber. The number of cells that 
were located on the bottom of the container or in suspension was 
subtracted to the plated cells total, giving the number of cells who 
actually adhered to the scaffolds. 
To observe cell morphologies, part of the scaffolds seeded with 
cells, were fixed 72 h after seeding, in 2.5% glutaraldehyde (SIC, 
Rome, Italy), 0.1 M sodium cacodylate (SIC), pH 7.3. They were 
subsequently washed three times for 10 min in the same buffer, 
post-fixed in 1% osmium tetroxide (SIC), 0.1 M sodium cacodylate, 
pH 7.3, on ice for 1 hour, washed three times for 10 min in the same 
buffer and dehydrated in ascending series of ethanol on ice. At the 
end of dehydration, samples were put in critical point drying (CPD 
Leica) placed on an aluminum stub with carbon tape, coated with 20 
nm of gold metal by sputter coating (208 HR sputter coater 
Cressington) and observed with a Zeiss ultraplus scanning electron  
microscopy. 
 
2.6. QK peptide synthesis and characterization 
 
The sequence KLT WQE LYQ LKY KGI of QK peptide was 
synthesized by solid phase peptide synthesis as C-terminally 
amidated and N-terminally acetylated derivates following standard 
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Fmoc chemistry protocol on a fully automated multichannel peptide 
synthesizer Biotage® Syro Wave™.  Rink-amide resin (substitution 
0.45 mmol/g) was used as solid support.  Coupling for each amino 
acid involves the following steps: 
-Deprotection of the N-terminal function (2 steps by 10 min) with a 
solution to a 30% Piperidine in DMF;  
-Coupling of 10 equivalent of Fmoc-AA, 9,9 equivalent of 
HOBT/HBTU (0,45 M solution in DMF) and 20 equivalent of 
DIPEA  (2 M solution in NMP) compared with 0.1 mmol scale 
synthesis; 
Three washes with DMF for 1 min were performed after each 
module. Acetylation was carried out with two treatment of 5 min 
with appropriate volume of a solution of acetic anhydride (2 
M)/DIPEA (O.55 M)/ HOBt (0.06 M). Cleavage from solid support 
was performed by treatment with a TFA/TIS/water (95:2, 5:2, 5, 
v/v/v) mixture for 2 hours at room temperature. Crude peptide was 
precipitated in cold diethyl-ether, dissolved in a water/acetonitrile 
(9:1, v/v) mixture and lyophilized. Preparative purification of 
synthetic peptides has been carried out on a RP-HPLC, (Waters 
2535 Quaternary Gradient Module), equipped with a 2489 
UV/Visible detector applying a linear gradient of acetonitrile (0, 1% 
TFA) from 20% to 80% in 20 min at flow rate of 7 mL/min. Peptide 
eluted at 41 % of acetonitrile concentration. The column used was 
an X-Bridge
TM
 BEH300 preparative 10× 100 mm C18, 5μm 
column. Peptide purity and identity were confirmed on an Agilent 
6530 Accurate-Mass Q-TOF LC/MS spectrometer with a gradient 
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of acetonitrile (0.1% Formic Acid) from water (0.1 % Formic Acid) 
of 5% to 60% in 7 min. The column used was the Symmetry C18 
3.5µm column (4.6 × 75 mm, Phenomenex, Torrance, CA, USA.). 
To obtain an accurate analysis by Total Ion Current chromatogram 
(TIC) an Extracted Ion Chromatogram (EIC) was extracted for 
[M+H
3+
]/3 = 651.7060 ± 0,5000 Da to obtain an area related only to 
the chemical species of interest. 
 
2.7. Reference peptide (RP) synthesis and characterization 
 
The sequence KGYLQTWILKEKL of RP peptide was synthesized 
by solid phase peptide synthesis as C-terminally amidated and N-
terminally acetylated derivates following standard Fmoc chemistry 
protocol on a fully automated multichannel peptide synthesizer 
Biotage® Syro Wave™.  Rink-amide resin (substitution 
0.45 mmol/g) was used as solid support. Coupling for each amino 
acid involves the following steps: 
-Deprotection of the N-terminal function (2 steps by 10 min) with a 
solution to a 30% Piperidine in DMF;  
-Coupling of 10 equivalent of Fmoc-AA, 9,9 equivalent of 
HOBT/HBTU (0,45 M solution in DMF) and 20 equivalent of 
DIPEA  (2 M solution in NMP) compared with 0.1 mmol scale 
synthesis; 
Three washes with DMF for 1 min were performed after each 
module. Acetylation was carried out with two treatment of 5 min 
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with appropriate volume of a solution of acetic anhydride (2 
M)/DIPEA (O.55 M)/ HOBt (0.06 M). Cleavage from solid support 
was performed by treatment with a TFA/TIS/water (95:2, 5:2, 5, 
v/v/v) mixture for 2 hours at room temperature. Crude peptide was 
precipitated in cold diethyl-ether, dissolved in a water/acetonitrile 
(9:1, v/v) mixture and lyophilized. Preparative purification of 
synthetic peptides has been carried out on a RP-HPLC, (Waters 
2535 Quaternary Gradient Module,) equipped with a 2489 
UV/Visible detector applying a linear gradient of acetonitrile (0, 1% 
TFA) from 20% to 80% in 20 min at flow rate of 7 mL/min. Peptide 
eluted at 39 % of acetonitrile concentration. The column used was 
an X-Bridge
TM
 BEH300 preparative 10× 100 mm C18, 5μm 
column. Peptide purity and identity were confirmed on an Agilent 
6530 Accurate-Mass Q-TOF LC/MS spectrometer with a gradient 
of acetonitrile (0.1% Formic Acid) from water (0.1 % Formic Acid) 
of 5% to 60% in 7 min. The column used was the Symmetry C18 
3.5µm column (4.6 × 75 mm, Phenomenex, Torrance, CA, USA.). 
To obtain an accurate analysis by Total Ion Current chromatogram 
(TIC) an Extracted Ion Chromatogram (EIC) was extracted for 
[M+H
3+
]/3 = 554.3330 ± 0,5000 Da to obtain an area related only to 
the chemical species of interest. 
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2.8. PLGA microparticles for controlled release of QK 
 
2.8.1. PLGA microparticles synthesis 
 
PLGA-Poloxamer and PLGA microspheres containing QK were 
prepared by the technique of multiple emulsion/solvent evaporation 
(W/O/W). A sterile solution in water (250 μl) containing QK, was 
emulsified by homogenization at 8000 rpm for 1 minutes 
(Ultraturrax T25 Basic, probe 8G, IKA, Germany), in a solution of 
2,5 ml of PLGA and poloxamer 188 (5:1 ratio) or only PLGA 
polymer in dichloromethane (10% w/v). The emulsion obtained was 
added to the external phase consisting of 100 ml of an aqueous PVA 
solution (1.5% w/v) (Mowiol® 40-88) and emulsified by an 
electronic stirrer (RZR 2102, Heidolph, Germany) at 450 rpm for 3 
hours, at room temperature, in order to facilitate the evaporation of 
the organic solvent and the precipitation of the polymer in the form 
of microparticles. Thereafter, microparticles were isolated and 
washed with 30 ml of distilled water 3 times, by centrifugation at 
5000 rpm for 10 minutes at 4⁰C, and subsequently subjected to a 
lyophilization cycle of 24 hours (0,001 atm , -60°C) (Freeze Dryer 
Alpha 1-4 LD plus, Martin Christ, DE). 
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2.8.2. Morphological analysis: Scanning electron 
microscopy observation 
 
The morphology and internal structure of the microspheres was 
visualized using scanning electron microscopy (SEM) (Zeiss, FEG 
Ultraplus, Germany). A small quantity of plain microspheres was 
sprinkled on the SEM stubs and coated using a SEM coating system 
(Cressingthon, 208 HR, UK) with 10nm of platinum-palladium 
under an argon atmosphere. Samples surface morphology was then 
observed and photographs were taken at 20000 Kv and different 
magnification. 
 
2.8.3. QK Encapsulation efficiency 
 
The amount of QK encapsulated within the microspheres was 
determined by degradation of the polymeric system. Briefly, 2 mg 
of microspheres were dissolved into 200 μl of Ethyl Acetate and 
QK was extracted into 100 μl of water. The suspension was 
maintained at room temperature for about 4 hours in agitation at 
400 rpm. The obtained solution was centrifuged at 15 rpm for 1 min 
and the QK peptide content in the aqueous phase as analyzed by (Q-
TOF) LC-MS. The results were expressed as encapsulation real or 
actual loading (µg QK encapsulate for mg of microspheres) and 
encapsulation efficiency (µg encapsulated real QK/ QK theoretical 
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X100) ± Standard deviation (SD) of the measurement carried out on 
five different batches.  
 
2.8.4. QK in vitro release kinetics 
 
In vitro release kinetics of QK peptide were made by suspending 2 
mg of lyophilized microspheres in 100 μl of PBS Ph 7.4 previously 
filtered through filter pores of 0.22 μm in diameter (Millex®, 
Millipore, USA). The samples were incubated in an incubator at 37 
°C and 50 rpm, to mimic the condition of release of the 
microspheres dispersed in a scaffold. At regular intervals of time, 
the sample were centrifuged at 300 rpm for 5 minutes at 4°C and 
the release media removed and replaced with the same volume of 
fresh PBS pH7.4. The samples taken were analyzed by (Q-TOF) 
LC-MS, to determine the amount of peptide released. The results 
were expressed as μg of QK released per mg of microparticles ± 
(SD) of the measurements carried out on five different batches. 
 
2.8.5. Bioactive scaffold “In Vitro” Release kinetics 
 
In vitro release studies of QK from sintered scaffolds were made by 
suspending one scaffold in 100 μL of PBS pH 7.4 previously 
filtered through filter pores of 0.22 μm in diameter (Millex®, 
Millipore, USA). The samples were incubated in an incubator at 37 
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° C and 50 rpm, to mimic the in vivo conditions. At regular 
intervals of time, the release media removed and replaced with the 
same volume of fresh PBS pH 7.4. The samples taken were 
analyzed by (Q-TOF) LC-MS, to determine the amount of peptide 
released. The results were expressed as μg of QK released per 
scaffold ± standard deviation (SD) of the measurement carried out 
on five different batches. 
 
2.8.6. In vitro sprouting angiogenesis assay 
 
Human Umbilical Vein Endothelial Cells (HUVECs) (Lonza) were 
grown in Medium 200 supplemented with LSGS kit (Life-
Technologies) at 37°C in 5% CO2 and 100% relative humidity 
(RH). At early passages (II-IV) they were employed in order to 
generate endothelial spheroids. After 3-4 days of culture, confluent 
HUVECs monolayers were trypsinized and 800 cells per spheroid 
were suspended in culture medium containing 0.25% (w/v) 
carboxymethylcellulose (Sigma), seeded into ultra-low-attachment 
round-bottom 96-well plates (Costar) and cultured as described to 
allow spheroids formation. After 24 h spheroids were harvested, 
centrifuged at 900 rcf for 15 minutes, suspended in 1.2mg/ml 
bovine skin collagen, transferred in 48-well plates (Falcon) and 
incubated. Once collagen polymerized M 200 culture medium 
supplemented with 2% FBS and 1% Pen Strep (10,000 U/mL 
penicillin G sodium, and 10,000 µg /mL streptomycin sulphate in 
0.85% saline) (Gibco) was added.  
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The proangiogenic activity of QK released from PLGA 
microspheres with or without poloxamer co-encapsulation at 
different QK concentrations was evaluated. A dose-response assay 
was performed in order to test the release aptitude of the depots as 
well as the bioactivity of the encapsulated peptide in 24h. In 
particular the concentrations of QK tested were 40, 80, and 160 
ng/ml. Briefly the amount of QK was calculated according to 
encapsulation efficiency of two formulations of microspheres and 
the final concentration of peptide to be tested. (40 80 and 160 
ng/ml). To know the number of microspheres able to release the 
exact concentration of QK, after 24h, the calculated amount of 
peptide was divided by the dose of QK/single microsphere. (µg 
QK/mg microspheres divided number of microspheres contained in 
1 mg, which is about 300 microparticles for microspheres of 200-
300 µm). 
Moreover, free QK released after 24h by a number of microspheres 
loaded in order to provide a presumed released peptide amount of 
40 ng/ml was tested. PLGA-poloxamer and PLGA microspheres 
were suspended in 100 µL of PBS at pH 7.4 previously filtered 
using a 0.22 μm pores filter. The samples were then incubated at 37 
°C and 50 rpm. After 24h the supernatant was removed and added 
to the spheroids culture medium.  
Spheroids were divided into four groups of eight samples each. 
Groups were identified and treated as follows: positive control (QK 
40 ng/ml), negative control (basal medium), QK released from 
microspheres embedded in collagen and from microspheres 
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suspended in PBS. Spheroids were then incubated at 37°C, with 5% 
CO2, and 100% RH. 
After a 24h culture, gels were observed by an inverted light 
microscope before being fixed with 4% paraformaldehyde for at 
least 40 minutes, rinsed with PBS buffer and stained with Phalloidin 
tetramethylrhodamine B isothiocyanate (Sigma-Aldrich) and Sytox 
green (Invitrogen) for actin microfilaments and cellular nuclei 
respectively. Sprouting was evaluated by a Leica SP5 confocal laser 
scanning microscope using a HCX APO LU-V-l 10.0 X 0.30 water 
objective lens. Samples were excited with a 488 nm argon laser for 
nuclei detection while for actin a 543nm He–Ne laser was 
employed. A 560–600 nm or a 505–530 nm emission was used to 
detect actin and nuclei respectively. Images processing and 
quantitative analysis were performed by Leica LAS AF Version 
2.7.3.9723 software. 
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Chapter 3 
 
3. Results and discussion  
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3.1. 3D Ordered Scaffolds: fabrication and morphological 
characterization 
 
The first step, which consists in the assembly of monolayers from 
single microspheres, is crucial for the fabrication of a design 
compliant 3D scaffold as much as the following stacking of 
multiple monolayers. It is also important to underline here that only 
a standardized ordered structure can have highly predictive 
mechanical and morphological properties along with the possibility 
of integrating precise functional elements (e.g. depots of biological 
factors) dispositions. 
As previously shown, PCL microspheres obtained by single 
emulsion-evaporation technique were arranged neatly on PDMS 
molds in order to obtain monolayers by chemical sintering with a 
solution of solvent-non-solvent for the PCL (Anisole / Ethanol). 
Shortly after pouring pure solvent - used for ease of implementation 
- ethanol was added to stop the swelling and control the process. 
The solvent caused the swelling of microspheres and connecting 
necks between them were subsequently formed. In all cases, necks 
were uniform (see Fig. 7). 
The next step was a multilayer structure sintering. The sintered 3D 
Ordered Scaffolds were built by stacking individual layers inside a 
Teflon box-shaped mold (l=5x5 mm , h=1,5 mm) and sintering 
them once again with a solution at a different concentration of 
solvent-non solvent, to ensure all necks formation between the 
microspheres. 
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Figure.7 Magnification of necks obtained by sintering with anisole 100% 
Compared to the first step, a further sintering with pure solvent 
(anisole 100%) would lead to polymer structure collapse. 
In order to avoid local collapses and /or pores occlusion is 
important to have more control on the swelling. The concentrations 
used are shown in Table 5. The effect of solvent concentration (% 
Anisole/% Ethanol) on scaffold morphology was evaluated by 
Micro-CT scanning. Based on the outcome of this measurement It 
was possible to optimize the processing conditions and obtain 
scaffolds with a well defined three-dimensional microstructure. 
The results are shown in Fig. 8, which depicts the effect of the 
concentration of the sintering solution on the degree of sintering 
between the microspheres. 
 
 
400 μm 
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Anisole-Ethanol 
70%-30% 
50%-50% 
30%-70% 
Table.5 Three different solvent (anisole/ethanol) concentrations for the last step 
of ordered 3D scaffold sintering 
Scaffolds sintered at 50%-50% and 70%-30% v/v Anisole/Ethanol, 
show partial occlusions in the porous network. In the case of 
sintering with a solution 30%-70% v/v Anisole/Ethanol, the 
microscopic analysis indicated that microspheres are packed 
together with a precise geometry and connecting necks are arranged 
uniformly and isotropically. The scaffold porosity is highly 
interconnected. 
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Figure.8 Section micrographs of 3D ordered scaffold; a), b), c) Anisole/ethanol 
30:70 (v/v); d) Anisole/ ethanol 50:50 (v/v); e) Anisole/ ethanol 70:3 (v/v) 
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3.2. Porosimetric MicroCT analysis 
 
To evaluate both qualitatively and quantitatively the degree of 
porosity, scaffolds pore size and volume and overall percentage of 
interconnected porosity were measured by a 3D image analysis of 
microCT tomographic scans. As explained in Chapter 2, each voxel 
in a 3D micrograph represents the X-ray absorption degree in the 
elementary volume. To assess scaffolds porosity, a binarization of 
the reconstructed images is therefore necessary; the black voxels 
will correspond to the empty volume. The software counts the white 
and black voxels, and the measurement of porosity is 
straightforward. This technique allows evaluating the pore size 
distribution or the interconnection degree, replacing more common 
– and less reliable - techniques such as mercury porosimetry. 
Scaffold porosity was compared with the theoretical porosity, using 
a simple geometrical model. If we consider a simple cubic unit cell 
for the microsphere lattice, each vertex of the cell contains 1/8 of 
microsphere, for a total volume occupation of one single 
microsphere. In this simple cubic lattice model, the edge of the cube 
is therefore equal to 2 times the radius of a microsphere. 
Porosity is a scalar quantity and it is generically defined as the ratio 
between the volume of voids and the total volume of the material 
considered. In the specific case of a simple cubic disposition of 
spheres it can be calculated by the following equation: 
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3 
= (2r)
3
 is the volume of the cube and VS = 4/3(πr
3
) is 
the sphere volume. 
Therefore 48% is the theoretical 3D scaffold porosity for a cubic 
disposition of microspheres, in accordance with the value measured 
by micro-CT scans analysis. 
 
Figure.9 Effect of solvent Anisole on the scaffold porosity 
The results in Fig. 9, show that the total porosity decreases from 48 
to 36% with increasing anisole concentration. The use of a high 
anisole concentration increases the swelling phenomenon of PCL 
microspheres. From a qualitative analysis of the microtomographic 
images it is possible to observe that scaffold porosity and the degree 
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of interconnection reduce because of the presence of irregular necks 
in the structure. 
 
3.3. Mechanical properties 
 
The mechanical strength of the sintered scaffolds, as well as the 
influence of Anisole solvent on the sintering process, was evaluated 
by mechanical compression tests. Test results are reported in Table 
6. 
Scaffold type Solvent/non solvent 
concentration 
ORDERED SCAFFOLD 30%-70% 
50%-50% 
70%-30% 
Table.6 Type of samples tested in different solvent-non solvent concentration 
Stress-strain curves gave information on some of the mechanical 
properties of the constructs. Compressive modulus was evaluated 
for each sample from the slope of the linear region of the stress–
strain curve. Then, compressive modulus of each scaffold type was 
calculated as the average of same-type samples. The graph in Fig.10 
compares the compressive moduli of each scaffold type. 
. 
. 
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Figure.10 Compressive modulus of scaffold at different Anisole/ Ethanol (v/v) 
concentration 
The results show that a change in solvent concentration has a 
significant effect on the elasticity of the polymeric 3D ordered 
scaffolds. Ordered scaffolds processed with a higher solvent 
concentration have a greater elastic modulus. This could be justified 
by the fact that when concentration increases, also the fraction of 
PCL that dissolves increases, filling the structure pores. 
Compressive mechanical properties of some PCL scaffolds 
manufactured through other fabrication techniques are reported in 
literatue [91]. According to Eshraghi et al., the compressive 
mechanical properties of bulk and porous PCL specimens were 
measured. Reported here, for bulk PCL, the mean compressive 
modulus was 299–317.1 MPa and the mean 0.2% offset yield 
strength was 10.3–12.5 MPa. While for 3D ordered scaffold 
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obtained by SLS technique and with a porosity of about 80%, 
compressive modulus was 15 MPa [92]. The compressive moduli of 
human trabecular bone range from 1 to 5000 MPa and the ultimate 
compressive strength ranges from 0.1 to 27.3 MPa [93] [94]. Thus, 
the order of magnitude of the elastic moduli of all the scaffolds 
types fabricated is consistent with that reported in literature and fall 
within the lower range of values reported for human trabecular 
bone. 
 
3.4. Surface treatments 
 
The surface properties of a material and the degree of hydrophilicity 
or hydrophobicity in particular play a very important role in cell 
adhesion during the initial period of cell seeding. This determines 
the successful formation of tissue constructs leading to the 
subsequent cell proliferation, differentiation and new tissue in-
growth. Because scaffolds are composed of PCL, a highly 
hydrophobic polymer, to facilitate the process of cell adhesion and 
proliferation they were subjected to two types of treatments: 
chemical and plasma treatments A morphological, mechanical and 
biological characterization of all these constructs was performed in 
order to compare them and underline their differences and benefits. 
To study the effect of the different treatments, the water contact 
angles on scaffolds surfaces were measured by a sessile drop 
technique, previously described. Conventionally if water contact 
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angle is smaller than 90° the solid surface is considered hydrophilic 
whereas if water contact angle is larger than 90° the solid surface is 
considered hydrophobic. Therefore, 2μL of water were deposited 
above every scaffold sample and measurements were carried out at 
three different time points: 
- At the moment the drop is deposited on the surface (0 seconds); 
- At an intermediate time (15 seconds); 
- A sufficiently long time to consider the drop as well positioned 
(30 seconds). 
The results obtained for each treated scaffold and for the untreated 
ones are showed in Table 7. 
TIME 
(s) 
UNTREATED 
SCAFFOLD 
NaOH  
TREATMENT 
PLASMA 
TREATMENT 
0 104,06 67,25 64,29 
15 102,83 0 0 
30 102,70 0 0 
Table.7 Measured static contact angle data at different time point on untreated, 
NaOH/EtOH treated and plasma treated PCL scaffold surface. 
The values in Table 8 show that untreated scaffolds have an angle 
greater than 90° for every time point, since the material is 
hydrophobic. It is also possible to observe that the drop deposited 
above the untreated samples remains on the surface and is not 
absorbed over time (Figure.11).  
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Figure.11 a), b), c) Water contact angle images at different time point on 
untreated scaffold; 
PCL becomes hydrophilic after the surface treatments as suggested 
by the measured angle. In these cases, the only frames that it was 
possible to obtain are those at zero seconds, or rather those obtained 
as soon as the drop has been deposited (Figure.12) because after a 
few milliseconds the droplet is completely absorbed 
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Figure.12 d) water contact angle on plasma treated scaffold, e) water contact 
angle on NaOH treated scaffold 
These results show clearly that both treatments are able to increase 
polymer wettability. Plasma surface modification and Ethanol/ 
sodium hydroxide treatments enhance the presence of polar 
functional group that not only increase the surface wettability of the 
polymer but also improve early cell attachment and protein 
adsorption.  
To confirm this hypothesis treated surfaces were also analyzed by 
scanning electron microscopy (SEM). Micrographs of NaOH 
treated 3D scaffolds show (Fig. 13) a more rippled surface 
compared to the control. While on the scaffolds treated with plasma, 
an increase in corrosion degree on the surface is noticeable 
Increasing surface roughness should inversely decrease the contact 
angle of water and, therefore, improve the hydrophilicity.  
 
82 
 
 
Figure.13 a) Micrograph of the surface of the untreated scaffold; b) Micrograph 
of the surface of the NaOH treated scaffold; c) Micrograph of the surface of the 
plasma treated scaffold 
 
3.5. Qualitative MicroCT analisys 
 
In order to evaluate scaffolds morphology, we performed a 
microCT analysis. The optimized processing conditions lead to 
sintered microspheres scaffolds with a well defined three-
dimensional microstructure, as illustrated before, in which the 
microspheres are packed together with a precise geometry and 
connecting necks are uniformly distributed. Scaffold porosity is 
highly interconnected. MicroCT analysis shows no significant 
structural differences between NaOH or plasma treated scaffolds 
and those untreated. (Figure.14) 
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Figure.14 Effect of different surface treatment on scaffold structure 
In accordance with the qualitative microCT analysis, it is clear that 
alkaline and plasma treatments did not affect the overall 
architecture of the scaffolds. 
A mechanical characterization of the samples was performed to 
determine their compressive strength, elastic modulus and 
deformation. From the data derived from each sample compression 
tests, stress-strain graphs were obtained (data not shown). 
Compressive modulus was calculated for each sample from the 
slope of the linear region of the stress–strain curve. Compressive 
moduli of each scaffold type were calculated as the average of same 
type samples. The graph in Fig. 15 compares the compressive 
moduli of each scaffold type. Tested samples show an elastic 
modulus in the range of 17-28 MPa approximately. Compressive 
moduli of scaffolds treated with plasma and NaOH are comparable, 
while compared to the untreated samples, a higher elastic modulus 
was obtained for all kinds of treatment performed. 
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Figure.15 Compressive modulus treated scaffold 
In both cases the order of magnitude of the elastic modulus of 
untreated scaffolds is consistent with that reported in literature for 
the ordered-porous scaffolds [93] [94]. 
 
3.6. Cells adhesion 
 
In order to observe the effect of surface treatment on the adhesion, 
proliferation, and differentiation of cells, HUVECs cells were 
cultured on the scaffolds with different treatments. No cells 
morphology difference is noticeable 6 hours after seeding regardless 
of treatment (Figure 16). In all three micrographs the cells 
morphology is equal, indicating that the different treatments do not 
affect the morphology. 
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Figure.16 Micrographs of cells on scaffolds: a) untreated, b) NaOH/EtOH 
treated and c) Plasma treated. 
Conversely, there is a noticeable difference in the number of cells 
adhering on the matrix surface. Plotting this number versus the type 
of surface treatment (Fig. 17), it can be observed that in both the 
scaffolds treated, cell adhesion is greater than the non-treated case 
and it is maximum for plasma in particular. This, as already pointed 
out, may be due to the greater number of polar components and the 
increased roughness in the plasma treated samples.  
.  
86 
 
 
Figure.17 type of treatment performed on the surface of the scaffold in function 
of cell adhesion 
 
3.7. QK peptide and RP characterization 
 
Peptides were synthesized by SPPS and purified by RP-HPLC. All 
peptides were obtained in good yields, in high pure and 
homogenous forms as assessed by (Q-TOF) LC-MS. Peptide 
identity was verified by ESI spectrometry and a comparison of 
experimental and calculated MW is reported below. Table.8. HPLC 
and (Q-TOF) LS-MS of QK peptide and RP shown in Figure 18 and 
19. 
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Molecular weight 
Theoretical, 
(g/mol) 
Molecular weight 
Experimental, (g/mol) 
QK 1952,33 1952,11 
RP 1661,02 1660,99 
Table.8 QK and RP peptide molecular weight 
 
 
Figure.18 LC-MS analysis of QK peptide 
RP-HPLC profile revealed at 280nm; b) UV absorption spectra of the peak; c) 
EIC spectra of m/z 651.7060±0.500 d) (Q-TOF) LC-MS spectrum of the peak at 
RT: 7.629min 
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Figure.19 LC-MS analysis of RP 
RP-HPLC profile revealed at 280nm; b) UV absorption spectra of the peak; c) 
EIC spectra of m/z 554.3330±0.500 d) (Q-TOF) LC-MS spectrum of the peak at 
RT: 7.254min. 
 
3.8. Efficiency encapsulation and release kinetics analysis by 
(Q-TOF) LC-MS 
 
To overcome problems related to QK peptide quantification in (Q-
TOF) LC-MS, we resorted to the use of an internal standard. A 
standard curve, at known concentration, of the standard peptide, has 
been developed in which the area of the EIC peak has been 
associated uniquely with the amount of peptide. Standard peptide 
was added in all experiments to determine the amount of QK 
peptide present in the mixture degradation and release. Ionization 
ability of the instrument in each experiment is defined comparing 
the standard EIC peak area and its standard curve. Comparing the 
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peak area of the standard peptide with the unknown of QK, we 
estimated univocally the amount of peptide in each mixture. 
 
3.9.  PLGA microparticles characterization 
 
The morphology of the two types of microspheres produced was 
evaluated by SEM. In order to underline the size distribution and 
surface appearance of the individual microspheres, we show in 
Figure 20 two micrographs at different magnification for each 
microsphere type. The microspheres look quite monodisperse and 
spherical in shape, regardless of formulation. The PLGA-poloxamer 
microspheres showed a smooth surface with micrometric pores 
(about 1 µm); conversely on the PLGA microspheres no pores or 
cavities were observed.  
As the SEM micrographs of the microspheres sections show, the 
inner structure of the PLGA-poloxamer microparticles contains a 
dense pore network; however, microspheres without poloxamer had 
a more compact matrix-type structure (Fig. 21). 
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Figure.20 micrographs of PLGA micropheres at different magnification; a), 
b)PLGA-Poloxamer microspheres; c), d) PLGA microspheres. 
 
Figure.21 a) micrographs of sections of PLGA-poloxamer microspheres;                
b) micrograph of section of PLGA microspheres. 
This morphological difference can affect the release of the 
encapsulated growth factors. A fast release of the bioactive agent is 
supported by the presence of a dense pore network, as in the case of 
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PLGA-Poloxamer microspheres, while the encapsulated protein in 
the case of PLGA microspheres releases in controlled and 
prolonged manner because of a surface without pores and a volume 
with few cavities,  
 
3.10. QK encapsulation efficiency and QK in vitro release 
from MS 
 
Table.9 shows the QK encapsulation efficiency of microspheres 
prepared by multiple emulsion/solvent evaporation (W/O/A). The 
specific formulation conditions gave PLGA-poloxamer 
microparticles with a QK encapsulation efficiency of about 73% 
(72.7 ± 2, 9% of QK; 1.2 ± 0, 1 µg QK for mg of microspheres). On 
the other hand PLGA-only microparticles have an encapsulation 
efficiency of 46% (45 ± 4, 6% of QK; 0.7 ± 0, 1 µg QK for mg of 
microspheres).  
Table9 PLGA-poloxamer and PLGA microparticles encapsulation efficiency and 
µg QK/mg microspheres 
 
Formulation Encapsulation efficiency µg QK/ mg 
microspheres 
PLGA-Poloxamer 72.7 % ± 2,9 1.2 ± 0,1 
PLGA 45% ± 4,6 0.7 ± 0,1 
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The high encapsulation efficiency of PLGA-Poloxamer 
microparticles could be related to a possible tendency of the peptide 
to interact with the poloxamer during the w/o primary emulsion. In 
vitro release tests were performed in order to analyze the effect of 
the two microparticle formulations. The QK release profile by 
PLGA microparticles is shown in Figure 22, and is expressed as µg 
of QK released in active form for 1 mg of microspheres as a 
function of time. As can be seen from the graph, the microparticles 
show an initial burst release of QK, in the first day of incubation, 
(32.7 ± 4.2% of QK), followed by a stable release.  
 
Figure.22 Release profile of QK by PLGA microparticles (µg\mg MS) 
These results suggest that the microparticles manufactured, when 
placed in three-dimensional substrates, have an excellent potential 
of promoting the activation of angiogenic processes, if careful 
control of the GF dose is provided. 
Conversely, PLGA-Poloxamer showed a higher release of peptide 
during the bust phase (89, 9 ± 3, 3% of QK) after just one day of 
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incubation. The higher QK release from the formulation containing 
poloxamer could be related to the stabilizing effect of the w/o 
primary emulsion. In particular the presence of poloxamer hinders 
the formation of the stabilizing film formed by the interaction 
between the peptide and the polymer which stabilizes the 
microdroplets of the w/o primary emulsion. This phenomenon leads 
to the coalescence of the aqueous microdroplets and, thus, to a more 
porous structure which goes from the inside to the surface of 
particles.  
 
3.11. QK in vitro release from scaffold 
 
The release profile of QK by the bioactive scaffolds prepared is 
expressed as µg of QK/scaffold released in active form as a function 
of time. We observe an initial release of QK in the first day of 
incubation, followed by a controlled release of QK. The Figure.23 
compares the release kinetics of QK from PLGA-Poloxamer and 
PLGA microspheres in a scaffold, expressed as µg QK per mg of 
microspheres 
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Figure.23 Release profile of QK by bioactive scaffold (µg\scaffold) 
This comparison shows that the trend of the release kinetics is 
practically the same, but much slower compared to the “free” 
microparticles (Fig. 24). This phenomenon can be ascribed to the 
process of sintering that through the formation of the junction points 
between microspheres reduces the surface area available to the free 
factor. In addition, it is possible that the peptide on the surface of 
the microspheres is removed during the sintering step in which there 
are several washings with ethanol. 
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Figure.24 Comparison between the release kinetics of QK from scaffolds and 
single microparticles (µg QK / mg MS) 
 
These results suggest that the bioactive scaffolds made from 
microparticles containing QK, have an enormous potential in 
inducing the formation of new blood vessels and consequently to 
promote the formation of a highly vascularized tissue. 
 
3.12. Bioactivity Assay 
 
The angiogenic potential of the encapsulated peptide was tested by 
spheroids angiogenesis assay on the basis of the angiogenic 
response measured in terms of sprouts number. We assayed the 
0,00 
0,20 
0,40 
0,60 
0,80 
1,00 
1,20 
0 5 10 15 20 25 
µ
g 
Q
K
 
Time, days 
PLGA microspheres, 
"free" 
PLGA microspheres in 
scaffold 
96 
 
effect of the peptide released by PLGA microparticles with and 
without poloxamer suspended in PBS or embedded in collagen. As 
shown in Figure 25, nude PLGA microparticles maintained an intact 
angiogenic potential of the encapsulated peptide compared to 
PLGA-poloxamer depots (QK 40ng/ml) 
 
Figure25 Difference in number of sprouts generated by QK released by 
microspheres in PBS and in collagen matrix 
Figure 26 shows confocal images of released QK bioactivity from 
two different formulations of microspheres in PBS on HUVEC 
spheroids embedded in the collagen matrix. More groups were 
tested in order to evaluate the dose-response correlation of the 
peptide released by microparticles embedded in collagen together 
with the spheroids.  
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Figure.26 Sprouting of HUVEC spheroids embedded in collagen 
We assayed the effect of three different concentrations of QK, 40, 
80 and 160 ng/ml, in comparison to 40 ng/ml of free peptide. In 
Figure 27 there is a clear correspondence between QK 
concentrations and the degree of angiogenic response, confirming 
the reliability of our release system. Figure 28 shows confocal 
images of HUVEC spheroids embedded in the collagen matrix at 
different QK concentrations. As shown, there is a clear increase of 
sprouts number, in response to high concentrations of peptide. 
(Nuclei are in green and actin filaments are in red) 
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Figure .27 Dose-response correlation of QK released by microparticles 
embedded in collagen on number of sprouts. 
 
Figure.28 Sprouting of HUVEC spheroids embedded in collagen with different 
QK concentration 
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Chapter 4 
4. Conclusion  
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This research work was focused on the fabrication and analysis of 
three-dimensional PCL scaffolds containing bioactive micro depots 
releasing pro-angiogenic peptides in-vitro. 
The first step aimed towards the optimization of a bottom-up 
fabrication technique in which single PCL microparticles are 
sintered chemically by a mixture of solvent/ non-solvent (Anisole/ 
ethanol). The effects of Anisole concentration on the scaffold 
structure, such as total percentage of pores, interconnection of pores 
network and mechanical properties, were thoroughly evaluated. In 
order to identify the optimal conditions for the fabrication of such 
structures, mechanical compressive stress tests, and morphological 
analyses by computed microtomography were performed. The 
results presented show that increasing anisole concentration 
decreases the percent porosity of the scaffold, which has been 
correlated to the swelling phenomenon of PCL microspheres. At the 
same time anisole concentration also influences the mechanical 
properties. A modification of solvent concentration had a significant 
effect on the elasticity of the polymeric structure. A higher solvent 
concentration gives rise to a greater elastic modulus.  
To improve cells adhesion and proliferation 2 types of treatments 
were performed on the surface of PCL scaffold: Plasma and basic 
hidrolys by NaOH/Ethanol solution. It was demonstrated that both 
treatments increase the number of adherent cells, without any 
significant alteration of the scaffolds structure. Plasma treatment, in 
particular, leads to an increase in elastic moduli and to a high 
number of cells interacting with the surface of the scaffold. 
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The second phase concerned the process optimization of PLGA 
microspheres synthesis. These DDS were later used as depots of 
QK, an angiogenic peptide mimicking Vascular Endothelial Growth 
Factor. To study the peptide bioactivity in-vitro HUVEC spheroids 
assays were performed. In particular, we have shown that the 
biological activity of QK, at 24 hours, is not altered by the 
formulation type of PLGA microspheres (with or without 
poloxamer). We also confirmed the reliability of our delivery 
system and assayed the effect of three different concentrations of 
QK on HUVEC spheroids in order to evaluate correspondence 
between QK concentrations and the degree of angiogenic response. 
In vitro studies of the release kinetics and bioactivity assays 
demonstrated that the PCL scaffold bioactivated with PLGA 
microparticles could be a potential tool for inducing the formation 
of the new blood vessels in-vivo. 
In conclusion, the bottom up approach allows the fabrication of an 
ordered highly standardized structure, with predictable mechanical 
and morphological properties and capable of releasing - from 
embedded, suitably designed micro depots - active biological 
factors in a predetermined crono-programmed manner. 
 
